Cargando…

Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data

Background. Rotavirus vaccination reduces childhood hospitalization in Africa, but cost-effectiveness has not been determined using real-world effectiveness and costing data. We sought to determine monovalent rotavirus vaccine cost-effectiveness in Malawi, one of Africa's poorest countries and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bar-Zeev, Naor, Tate, Jacqueline E., Pecenka, Clint, Chikafa, Jean, Mvula, Hazzie, Wachepa, Richard, Mwansambo, Charles, Mhango, Themba, Chirwa, Geoffrey, Crampin, Amelia C., Parashar, Umesh D., Costello, Anthony, Heyderman, Robert S., French, Neil, Atherly, Deborah, Cunliffe, Nigel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825884/
https://www.ncbi.nlm.nih.gov/pubmed/27059360
http://dx.doi.org/10.1093/cid/civ1025
_version_ 1782426262769238016
author Bar-Zeev, Naor
Tate, Jacqueline E.
Pecenka, Clint
Chikafa, Jean
Mvula, Hazzie
Wachepa, Richard
Mwansambo, Charles
Mhango, Themba
Chirwa, Geoffrey
Crampin, Amelia C.
Parashar, Umesh D.
Costello, Anthony
Heyderman, Robert S.
French, Neil
Atherly, Deborah
Cunliffe, Nigel A.
author_facet Bar-Zeev, Naor
Tate, Jacqueline E.
Pecenka, Clint
Chikafa, Jean
Mvula, Hazzie
Wachepa, Richard
Mwansambo, Charles
Mhango, Themba
Chirwa, Geoffrey
Crampin, Amelia C.
Parashar, Umesh D.
Costello, Anthony
Heyderman, Robert S.
French, Neil
Atherly, Deborah
Cunliffe, Nigel A.
author_sort Bar-Zeev, Naor
collection PubMed
description Background. Rotavirus vaccination reduces childhood hospitalization in Africa, but cost-effectiveness has not been determined using real-world effectiveness and costing data. We sought to determine monovalent rotavirus vaccine cost-effectiveness in Malawi, one of Africa's poorest countries and the first Gavi-eligible country to report disease reduction following introduction in 2012. Methods. This was a prospective cohort study of children with acute gastroenteritis at a rural primary health center, a rural first referral–level hospital and an urban regional referral hospital in Malawi. For each participant we itemized household costs of illness and direct medical expenditures incurred. We also collected Ministry of Health vaccine implementation costs. Using a standard tool (TRIVAC), we derived cost-effectiveness. Results. Between 1 January 2013 and 21 November 2014, we recruited 530 children aged <5 years with gastroenteritis. Costs did not differ by rotavirus test result, but were significantly higher for admitted children and those with increased severity on Vesikari scale. Adding rotavirus vaccine to the national schedule costs Malawi $0.42 per dose in system costs. Vaccine copayment is an additional $0.20. Over 20 years, the vaccine program will avert 1 026 000 cases of rotavirus gastroenteritis, 78 000 inpatient admissions, 4300 deaths, and 136 000 disability-adjusted-life-years (DALYs). For this year's birth cohort, it will avert 54 000 cases of rotavirus and 281 deaths in children aged <5 years. The program will cost $10.5 million and save $8.0 million in averted healthcare costs. Societal cost per DALY averted was $10, and the cost per rotavirus case averted was $1. Conclusions. Gastroenteritis causes substantial economic burden to Malawi. The rotavirus vaccine program is highly cost-effective. Together with the demonstrated impact of rotavirus vaccine in reducing population hospitalization burden, its cost-effectiveness makes a strong argument for widespread utilization in other low-income, high-burden settings.
format Online
Article
Text
id pubmed-4825884
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-48258842016-04-11 Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data Bar-Zeev, Naor Tate, Jacqueline E. Pecenka, Clint Chikafa, Jean Mvula, Hazzie Wachepa, Richard Mwansambo, Charles Mhango, Themba Chirwa, Geoffrey Crampin, Amelia C. Parashar, Umesh D. Costello, Anthony Heyderman, Robert S. French, Neil Atherly, Deborah Cunliffe, Nigel A. Clin Infect Dis Africa Background. Rotavirus vaccination reduces childhood hospitalization in Africa, but cost-effectiveness has not been determined using real-world effectiveness and costing data. We sought to determine monovalent rotavirus vaccine cost-effectiveness in Malawi, one of Africa's poorest countries and the first Gavi-eligible country to report disease reduction following introduction in 2012. Methods. This was a prospective cohort study of children with acute gastroenteritis at a rural primary health center, a rural first referral–level hospital and an urban regional referral hospital in Malawi. For each participant we itemized household costs of illness and direct medical expenditures incurred. We also collected Ministry of Health vaccine implementation costs. Using a standard tool (TRIVAC), we derived cost-effectiveness. Results. Between 1 January 2013 and 21 November 2014, we recruited 530 children aged <5 years with gastroenteritis. Costs did not differ by rotavirus test result, but were significantly higher for admitted children and those with increased severity on Vesikari scale. Adding rotavirus vaccine to the national schedule costs Malawi $0.42 per dose in system costs. Vaccine copayment is an additional $0.20. Over 20 years, the vaccine program will avert 1 026 000 cases of rotavirus gastroenteritis, 78 000 inpatient admissions, 4300 deaths, and 136 000 disability-adjusted-life-years (DALYs). For this year's birth cohort, it will avert 54 000 cases of rotavirus and 281 deaths in children aged <5 years. The program will cost $10.5 million and save $8.0 million in averted healthcare costs. Societal cost per DALY averted was $10, and the cost per rotavirus case averted was $1. Conclusions. Gastroenteritis causes substantial economic burden to Malawi. The rotavirus vaccine program is highly cost-effective. Together with the demonstrated impact of rotavirus vaccine in reducing population hospitalization burden, its cost-effectiveness makes a strong argument for widespread utilization in other low-income, high-burden settings. Oxford University Press 2016-05-01 2016-04-07 /pmc/articles/PMC4825884/ /pubmed/27059360 http://dx.doi.org/10.1093/cid/civ1025 Text en © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Africa
Bar-Zeev, Naor
Tate, Jacqueline E.
Pecenka, Clint
Chikafa, Jean
Mvula, Hazzie
Wachepa, Richard
Mwansambo, Charles
Mhango, Themba
Chirwa, Geoffrey
Crampin, Amelia C.
Parashar, Umesh D.
Costello, Anthony
Heyderman, Robert S.
French, Neil
Atherly, Deborah
Cunliffe, Nigel A.
Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data
title Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data
title_full Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data
title_fullStr Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data
title_full_unstemmed Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data
title_short Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data
title_sort cost-effectiveness of monovalent rotavirus vaccination of infants in malawi: a postintroduction analysis using individual patient–level costing data
topic Africa
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825884/
https://www.ncbi.nlm.nih.gov/pubmed/27059360
http://dx.doi.org/10.1093/cid/civ1025
work_keys_str_mv AT barzeevnaor costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT tatejacquelinee costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT pecenkaclint costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT chikafajean costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT mvulahazzie costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT wacheparichard costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT mwansambocharles costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT mhangothemba costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT chirwageoffrey costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT crampinameliac costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT parasharumeshd costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT costelloanthony costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT heydermanroberts costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT frenchneil costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT atherlydeborah costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata
AT cunliffenigela costeffectivenessofmonovalentrotavirusvaccinationofinfantsinmalawiapostintroductionanalysisusingindividualpatientlevelcostingdata